Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 3,860 Shares

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 3,860 shares of the business’s stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $36.22, for a total value of $139,809.20. Following the completion of the sale, the insider now directly owns 247,173 shares of the company’s stock, valued at approximately $8,952,606.06. The trade was a 1.54 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, March 5th, Carl Dambkowski sold 1,590 shares of Apogee Therapeutics stock. The shares were sold at an average price of $30.48, for a total transaction of $48,463.20.
• On Wednesday, February 5th, Carl Dambkowski sold 3,520 shares of Apogee Therapeutics stock. The stock was sold at an average price of $40.69, for a total transaction of $143,228.80.

Apogee Therapeutics Price Performance

APGE stock opened at $32.32 on Monday. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -13.36 and a beta of 1.72. The company has a 50-day moving average of $37.21 and a two-hundred day moving average of $45.40. Apogee Therapeutics, Inc. has a 52-week low of $29.10 and a 52-week high of $63.50.

Apogee Therapeutics (NASDAQ:APGE) last announced its earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.25). Equities analysts expect that Apogee Therapeutics, Inc. will post -3.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Apogee Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of APGE. Point72 Asset Management L.P. boosted its holdings in Apogee Therapeutics by 162.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 707,268 shares of the company’s stock valued at $41,545,000 after purchasing an additional 438,036 shares during the period. Geode Capital Management LLC raised its position in shares of Apogee Therapeutics by 11.2% during the third quarter. Geode Capital Management LLC now owns 823,839 shares of the company’s stock valued at $48,401,000 after buying an additional 82,978 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Apogee Therapeutics by 17.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 280,428 shares of the company’s stock valued at $16,472,000 after buying an additional 41,686 shares during the period. Barclays PLC grew its position in Apogee Therapeutics by 369.2% during the third quarter. Barclays PLC now owns 365,046 shares of the company’s stock worth $21,443,000 after buying an additional 287,243 shares in the last quarter. Finally, Intech Investment Management LLC bought a new position in Apogee Therapeutics during the third quarter valued at about $300,000. Institutional investors own 79.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Wedbush reiterated an “outperform” rating and issued a $90.00 price objective on shares of Apogee Therapeutics in a report on Tuesday, March 11th. Guggenheim reiterated a “buy” rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Finally, Citigroup began coverage on Apogee Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $95.00 price objective on the stock. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $92.17.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.